Zydus Lifesciences Limited has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for ZITUVIMET, a combination of Sitagliptin and Metformin hydrochloride, designed to improve glycemic control in adults with type 2 diabetes mellitus as part of a comprehensive lifestyle intervention. ZITUVIMET: A New Adjunct in Diabetes Care With the […]
Zydus Lifesciences Limited announced today that the U.S. Food and Drug Administration (FDA) has granted approval for its New Drug Application (NDA) for ZITUVIO (Sitagliptin) tablets in three dosages: 25 mg, 50 mg, and 100 mg. What is ZITUVIO? Containing the active ingredient Sitagliptin, ZITUVIO functions as a dipeptidyl peptidase-4 (DPP-4) inhibitor. It’s specifically designed […]
Zydus Lifesciences (Cadila Healthcare) has rolled out the molecule Sitagliptin in India under the Sitaglyn and Siglyn brand names for the treatment of Type 2 diabetes in the country. Sitaglyn and Siglyn are intended to be delivered as an oral solution. According to Zydus Lifesciences, Sitaglyn drug is said to offer best-in-class achievement of the […]
Zydus Cadila said that its subsidiary has been granted tentative approval from the US Food and Drug Administration (FDA) for its new drug application (NDA) for Sitagliptin base 25, 50, and 100 mg tablets. The Indian pharma company said that Sitagliptin base has the active moiety Sitagliptin in a different form than the one used […]